Posted by Michael Wonder on 29 Sep 2022
FDA approves new treatment option for patients with ALS
29 September 2022 - The US FDA today approved Relyvrio (sodium phenylbutyrate/taurursodiol) to treat patients with amyotrophic lateral sclerosis, commonly referred to as Lou Gehrig’s disease.
The efficacy of Relyvrio for the treatment of amyotrophic lateral sclerosis was demonstrated in a 24 week, multi-centre, randomised, double-blind, placebo-controlled, parallel-group trial.
